Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Survodutide for Adults with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Findings from the SYNCHRONIZE-MASLD Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • August 25, 2026

Share

Clinical Scorecard: Correction Notice: Survodutide for Adults with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Findings from the SYNCHRONIZE-MASLD Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

At a Glance

CategoryDetail
ConditionObesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Key MechanismsSurvodutide as a treatment option
Target PopulationAdults with obesity and metabolic dysfunction
Care SettingClinical trial setting

Key Highlights

  • Correction of author affiliations in the SYNCHRONIZE-MASLD Investigators list
  • Correction of a numerical typographical error in treatment-discontinuation frequencies
  • Amendment of the Extended Data Fig. 5 caption from 'week 48' to 'week 52'

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Adults with obesity and metabolic dysfunction-associated steatotic liver disease

          Findings from the SYNCHRONIZE-MASLD trial

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

            • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

            • August 25, 2026

            Related Content

            Correction: Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects

            Ascending Colon HGD ESD Procedure with DiLumen C1 and IgE Grasper

            In this video Dr. Molham Abdulsamad of Geisinger Health demonstrates how Lumendi’s DiLumen™ C1  overtube and IgE Grasper improve access, stability and provide independent, multidirectional traction during resection of an ascending colon polyp adjacent to the hepatic flexure.

            • August 21, 2026

            • 1 min
            Mesenchymal R-spondin 3 promotes an immunogenic tumor microenvironment with adaptive immune resistance in human gastric adenocarcinoma